| Autor: |
Ceda GP; Department of Internal Medicine and Biomedical Sciences, Section of Geriatrics, University of Parma, Parma, Italy. gpceda@unipr.it, Dall'Aglio E, Salimbeni I, Rocci A, Mazzoni S, Corradi F, Cattadori E, Visioli S, Banchini A, Ceresini G, Valenti G, Hoffman AR |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of endocrinological investigation [J Endocrinol Invest] 2002; Vol. 25 (10 Suppl), pp. 24-8. |
| Abstrakt: |
Heart failure is a complex syndrome characterized by the activation of hemodynamic, immunologic and neurohormonal systems, which have beneficial effects in the short run, but will ultimately lead to secondary end-organ damage with worsening of LV remodeling and subsequent cardiac decompensation. A very important role seems to be played by modifications of the pituitary hormone systems. Due to the neurohormonal activation there is an increase in the activity in the renin angiotensin system, in the adrenergic nervous system, and in the cytokine system. In heart failure there is a decrease in many anabolic hormones, such as a decrease of GH and IGF-I, of DHEA/DHEAS with normal or increased F, and a decrease of LH and sex steroids, resulting in an important catabolic drive, capable of contributing to the development of cardiac failure and to sarcopenia and/or cachexia, frequently observed in the advanced stages of the disease. However, these hormone alterations have been described in relatively young patients with chronic heart failure, since the mean age of all the subjects studied was of about 60 yr and none of the studies have specifically addressed this issue in the very old patients, who represent the largest portion of population affected by this pathological condition. The role of hormone replacement therapy needs to be verified in a population of elderly patients with heart failure. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink